Wed.Nov 03, 2021

article thumbnail

Cystic fibrosis group partners with Moderna founder to find better, potentially curative treatments

Bio Pharma Dive

With an initial investment of $20 million, the collaboration will use technologies from various Flagship-backed companies to discover and develop new therapies for the disease.

article thumbnail

Digital therapeutic cuts opioid use disorder care costs, says study

pharmaphorum

A real-world study of digital therapeutic (DTx) for opioid use disorder has found that patient show used it had 46% fewer hospital stays than a control group, saving more than $2,700 over a nine-month period. The study of Pear Therapeutics’ reSET-O found that the total cost of hospital and clinician costs were $11,141 among 64 patients who were prescribed the DTx but didn’t use it, but fell to $8,733 among active users of the 12-week course.

Drugs 132
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Pfizer gene therapy research delayed by trial changes, safety questions

Bio Pharma Dive

Data readouts for Pfizer's hemophilia gene therapies are now expected later than previously forecast, while the company also works through modifying a trial of its Duchenne treatment.

article thumbnail

Advanced breast cancer patients denied opportunities to join clinical trials

Scienmag

Clinicians and the wider research community involved in treating advanced breast cancer (ABC) need to do more to help and encourage patients to join clinical trials, according to a patient advocate who is leading a study that shows only 14% of ABC patients in the UK have been recruited to a trial. Credit: Lesley Stephen […].

article thumbnail

The New Age of Decentralized Clinical Trials

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

article thumbnail

EMA starts review of Enhertu for HER2+ gastric cancer

pharmaphorum

The EMA has started its review of AstraZeneca and Daiichi Sankyo’s Enhertu for a second indication, as a second-line treatment for HER2-positive gastric cancer. If approved the new indication for antibody-drug conjugate Enhertu (trastuzumab deruxtecan) will add to its first EU approval in advanced HER2-positive breast cancer after two or more HER2-targeted therapies.

article thumbnail

Novartis Sells Shares Back to Roche for $20.7 Billion

BioSpace

For the past 20 years, Novartis has held a 33% stake in Roche, its Basel, Switzerland neighbor. Now, Novartis has divested its one-third stake to Roche for a whopping $20.7 billion.

98

More Trending

article thumbnail

Magnus Medical’s Neurostimulation Technology Granted FDA Breakthrough Device Designation

XTalks

Neurostimulation technology company Magnus Medical received Breakthrough Device Designation from the US Food and Drug Administration (FDA) for its personalized, rapid-acting neurostimulation system for the treatment of major depressive disorder (MDD). The system is indicated for individuals that have not sufficiently responded to antidepressants or other treatments for the condition.

article thumbnail

Calling for patents in electronic imaging

Scienmag

BELLINGHAM, Washington, USA — The Journal of Electronic Imaging (JEI), which is co-published by SPIE, the international society for optics and photonics, and IS&T, is inviting researchers to submit papers covering their patents, both granted and pending, in the electronic imaging field. Accepted submissions will be published in a special section of JEI in September 2022 and will highlight […].

article thumbnail

ICEBERG study demonstrates improved outcomes of nasal spray for TRD

Pharma Times

Back in 2019, esketamine was commercialised as Spravato, described as a “breakthrough” medication used to treat depression

114
114
article thumbnail

Study identifies cancer features that could guide personalized radiotherapy

Scienmag

PITTSBURGH, Nov. 3, 2021 – Radiation can be a powerful cancer therapy, but it doesn’t work for everyone. A new study identifies tumor features linked with resistance to radiotherapy, an important advance toward developing individualized cancer treatments. Credit: UPMC PITTSBURGH, Nov. 3, 2021 – Radiation can be a powerful cancer therapy, but it doesn’t work for everyone.

article thumbnail

Roles and Responsibilities of Specialized Clinical Supply Experts

When selecting a clinical supply provider, consideration often focuses upon the manufacturing, packaging, storage and distribution capabilities available that will, at face-value, be sufficient to meet the needs of the sponsor and their trial. However, there are human-based and knowledge-driven factors that are often overlooked that go beyond these basic physical capabilities and are integral to the development and delivery of high performing clinical supply chains.

article thumbnail

Novartis signs $1.3bn deal with UK-based Dunad

Pharma Times

Dunad will apply its own platform to generate the novel covalent and targeted protein degrading small molecule drugs

Protein 115
article thumbnail

MU study examines benefits, challenges of telehealth in nursing homes during pandemic

Scienmag

COLUMBIA, Mo. — The COVID-19 pandemic caused nursing homes to rapidly change their policies overnight. Telehealth was instantly adopted widely in an effort to reduce stress on the health care system by keeping residents safe and avoiding unnecessary transfers to already-overwhelmed hospitals. Credit: MU Sinclair School of Nursing COLUMBIA, Mo. — The COVID-19 pandemic caused […].

Nurses 91
article thumbnail

COVID-19 Vaccines Drive Q3 Revenue for Moderna and Pfizer

BioSpace

Both Moderna and Pfizer reported third-quarter financials this week, and it was instantly obvious that the COVID-19 vaccines are huge profit drivers for the companies.

article thumbnail

UTEP awarded $6.1 million grant for cancer research and detection

Scienmag

The University of Texas at El Paso is leading new research into Hispanic cancer disparities and early cancer detection with $6.1 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT). Credit: UTEP Marketing and Communications The University of Texas at El Paso is leading new research into Hispanic cancer disparities and […].

article thumbnail

The New Age of Decentralized Clinical Trials

This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.

article thumbnail

COVID-19 Update: UK Approves Molnupiravir, WHO Authorizes Ocugen/Bharat Vaccine

BioSpace

Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.

article thumbnail

Hungry caterpillars an underappreciated driver of carbon emissions

Scienmag

A study led by the University of Cambridge has found that periodic mass outbreaks of leaf-munching caterpillars can improve the water quality of nearby lakes – but may also increase the lakes’ carbon dioxide emissions. Credit: John Gunn A study led by the University of Cambridge has found that periodic mass outbreaks of leaf-munching caterpillars […].

article thumbnail

COVID-19 is a Sprint AND a Marathon, Requiring New and Better Vaccines

BioSpace

While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.

article thumbnail

Prostate cancer treatment: an encouraging combination therapy

Scienmag

This is among the findings of a phase lll clinical trial published in The Lancet Oncology by an international research team led by Dr.?Fred Saad, a researcher at the CHUM Research Centre, a Université de Montréal professor and the holder of the Raymond Garneau Chair in Prostate Cancer Research. Credit: CHUM This is among the […].

article thumbnail

Accelerating Clinical Supply Through Integrated Drug Development

As the development pipeline for new drugs continues to grow, biopharmaceutical companies are re-evaluating how to best manage and balance resources across an increasing number of development projects and complex clinical trials. There are two approaches that can be used to speed a drug from development to clinic faster: timeline compression and parallel processing, but only one that considers the benefits of integrating clinical supply into the overall drug development process.

article thumbnail

Origin of Alzheimer's Could Differ from Accepted Theories

BioSpace

Researchers with the University of Cambridge in the UK for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.

article thumbnail

Argonne captures 3 R&D 100 Awards for innovative technology

Scienmag

Argonne award winners chosen from large, competitive pool in global competition. Credit: (Image by Argonne National Laboratory.) Argonne award winners chosen from large, competitive pool in global competition. Three technologies developed by researchers at the U.S. Department of Energy’s (DOE) Argonne National Laboratory and partner organizations have been named as 2021 R&D 100 Award winners, building on a decades-long […].

article thumbnail

Four Biopharmas Rake in Funds for Novel Therapeutics

BioSpace

The proceeds will be used to advance the development of their ePLC platform, treatment for chronic Hepatitis B, and a novel class of anti-cancer therapies.

article thumbnail

Quillwort genome highlights divergences in aquatic CAM photosynthesis

Scienmag

ITHACA, NY, November 3, 2021 — Credit: Yao-Moan Huang ITHACA, NY, November 3, 2021 — The humble quillworts are an ancient group of about 250 small, aquatic plants that have largely been ignored by modern botanists. A group of researchers, led by Boyce Thompson Institute’s Fay-Wei Li, have sequenced the first quillwort genome and uncovered […].

Genome 86
article thumbnail

How Machine Learning Drives Clinical Trial Efficiency

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

article thumbnail

Zymergen Eliminates 220 Jobs in Restructuring Push

BioSpace

?The job cuts, which affect a variety of functions and levels, are expected to slow its cash burn rate and leave the company with sufficient funds on hand to operate until mid-2023.

81
article thumbnail

Closer look at unexamined interactions could improve drug purification process

Scienmag

TROY, N.Y. — The process of purifying biopharmaceutical drugs remains a costly and time-consuming challenge. A deeper understanding of how unwanted elements within biomanufactured proteins bind to the molecules developed to remove them could help researchers make purity processes more efficient, more complex, and increasingly scalable. Credit: Rensselaer Polytechnic Institute TROY, N.Y. — The process […].

Drugs 86
article thumbnail

Global Roundup: Singapore Researchers Create Atlas of Gastric Cancer

BioSpace

Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.

article thumbnail

History of insect invasions offer insight into the future

Scienmag

Over the past two centuries, thousands of non-native insects have hitchhiked to the United States in packing material, on live plants, and in passenger baggage. Scientists with two U.S. Department of Agriculture (USDA) agencies and their partners used the history of live plant imports and invasion by a common group of insects to estimate the […].

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

The global landscape of clinical trials is rapidly changing as studies become more complex. An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays. Demand-led supply and direct-to-patient distribution are next-generation solutions that are helping to meet these growing needs, allowing for more streamlined processes and patient-centric studies.

article thumbnail

Report: North America is key hub for the development of porphyria therapies

BioPharma Reporter

The porphyria therapies market is projected to grow at an annualized rate of 10.97% during the period 2021-2030, claims a new report from Roots Analysis.

article thumbnail

A natural CO2-sink thanks to symbiotic bacteria

Scienmag

Seagrasses are widespread in shallow coastal regions of both temperate and tropical seas, covering up to 600,000 square kilometers, which is roughly the area of France. They form the basis of the entire ecosystem, which is home to numerous organisms, some of them endangered species such as turtles, seahorses and manatees, and nursery ground for […].

article thumbnail

Psychedelics startup Beckley attracts Janssen neuroscience VP

pharmaphorum

Psychedelic medicines specialist Beckley Psytech has enticed a senior figure in Janssen’s neuroscience division to take on the role of its chief medical officer as it ushers its first drugs through clinical trials. Dr Frank Wiegand is joining Beckley after more than two decades at Janssen and parent company Johnson & Johnson, most recently as vice president for global medical affairs and market access for neuroscience.

article thumbnail

Researchers identify molecule that blocks immune cells from entering and killing breast tumors

Scienmag

WASHINGTON (Nov. 3, 2021) – George Washington University researchers have identified a key molecule in certain kinds of breast cancers that prevent immune cells from entering tumors and killing the cancer cells inside. The paper and its findings, published today in Nature, could pave the way toward a new treatment for certain kinds of aggressive […].

article thumbnail

Deliver Fast, Flexible Clinical Trial Insights with Spotfire

Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.